此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

癌症患者的基因组分析

2026年9月23日 更新者:Memorial Sloan Kettering Cancer Center

The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Some of these mutations are important for the cancer cells to survive while others are not. The goal of this study is test cancer for certain mutations using leftover tumor tissue from a previous surgery or biopsy. Participants will also be asked to provide a tube of blood cheek (also known as a buccal) swab, or a saliva sample that contains normal genes for comparison.

The purpose of Part B of this study is to:

Understand how genetic changes in tumor effect the chance of responding to experimental cancer treatment. Understand how the genes in the tumor change overtime in response to targeted cancer treatment.

研究概览

研究类型

观察性的

注册 (估计的)

200

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:David Solit, MD
  • 电话号码:646-888-2641

研究联系人备份

  • 姓名:Zsofia Stadler, MD
  • 电话号码:646-888-4039

学习地点

    • Connecticut
      • Bridgeport、Connecticut、美国、06606
        • 尚未招聘
        • St. Vincent (Data Collection Only)
        • 接触:
          • Christopher Iannuzzi, MD
          • 电话号码:203-576-6000
      • Hartford、Connecticut、美国、06102
        • 尚未招聘
        • Hartford Healthcare Cancer Institute @ Hartford Hospital
        • 接触:
          • Andrew Salner, MD
          • 电话号码:860-972-2803
      • Norwalk、Connecticut、美国、06850
        • 招聘中
        • Norwalk Hospital
        • 接触:
          • Linda Vahdat, MD
          • 电话号码:203-845-4811
    • Florida
      • Miami、Florida、美国、33143
        • 招聘中
        • Baptist Alliance MCI
        • 接触:
          • John Diaz, MD
          • 电话号码:786-596-2000
    • New Jersey
      • Basking Ridge、New Jersey、美国、07920
        • 招聘中
        • Memorial Sloan Kettering Basking Ridge
        • 接触:
          • David Solit, MD
          • 电话号码:646-888-2641
      • Middletown、New Jersey、美国、07748
        • 招聘中
        • Memorial Sloan Kettering Monmouth
        • 接触:
          • David Solit, MD
          • 电话号码:646-888-2641
      • Montvale、New Jersey、美国、07645
        • 招聘中
        • Memorial Sloan Kettering Bergen
        • 接触:
          • David Solit, MD
          • 电话号码:646-888-2641
    • New York
      • Brooklyn、New York、美国、11203
        • 招聘中
        • Kings County Hopsital Center
        • 接触:
          • Jason Gonsky, MD
          • 电话号码:718-245-2847
      • Commack、New York、美国、11725
        • 招聘中
        • Memorial Sloan Kettering Cancer Commack
        • 接触:
          • David Solit, MD
          • 电话号码:646-888-2641
      • Harrison、New York、美国、10604
        • 招聘中
        • Memorial Sloan Kettering Westchester
        • 接触:
          • David Solit, MD
          • 电话号码:646-888-2641
      • Jamaica、New York、美国、11432
        • 招聘中
        • Queens Cancer Center of Queens Hospital
        • 接触:
          • Debra Ferman, MD
          • 电话号码:718-579-6021
      • New York、New York、美国、10065
        • 招聘中
        • Memorial Sloan Kettering Cancer Center
        • 接触:
          • David Solit, MD
          • 电话号码:646-888-2641
        • 接触:
          • Zsofia Stadler, MD
          • 电话号码:646-888-4039
        • 首席研究员:
          • David Solit, MD
      • New York、New York、美国、10029
        • 招聘中
        • Metropolitan Hospital Center
        • 接触:
          • Anitha Srinivasan, MD
          • 电话号码:212-423-6262
      • New York、New York、美国、10035
        • 招聘中
        • Ralph Lauren Center for Cancer Care and Prevention
        • 接触:
          • Lewis P. Kampel, MD
          • 电话号码:646-422-4474
      • Richmond Hill、New York、美国、11418
        • 招聘中
        • Medisys Health Network (Data Collection Only)
        • 接触:
          • Rosa Nouvini, MD
          • 电话号码:718-206-6000
      • The Bronx、New York、美国、10451
        • 招聘中
        • NYC Health & Hospitals /Lincoln Medical Center
        • 接触:
          • Monica Reddy Muppidi, MD
          • 电话号码:718-579-4977
        • 首席研究员:
          • Monica Reddy Muppidi, MD
      • Uniondale、New York、美国、11553
        • 招聘中
        • Memorial Sloan Kettering Nassau
        • 接触:
          • David Solit, MD
          • 电话号码:646-888-2641
    • Pennsylvania
      • Allentown、Pennsylvania、美国、18103
        • 招聘中
        • Lehigh Valley Health Network
        • 接触:
          • Suresh Nair, MD
          • 电话号码:610-402-7880

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients with solid or hematologic cancers who may be and considered potential candidates for a therapeutic protocol will be recruited to Part A of this study. Enrollment to therapeutic clinical trials will not be contingent on enrollment in this protocol.

Part B: Research Collection Cohort Patients potentially appropriate will be identified by their treating physician in each participating Disease Management Team.

描述

Inclusion Criteria:

Part A:

  • Patients with a history of cancer or patients without a documented cancer history undergoing a surgical procedure, endoscopy, biopsy, or liquid biopsy (for example cell free DNA testing) to confirm or exclude a cancer diagnosis, or
  • Any participant having a test or procedure that has the potential to provide a specimen that can be banked for future research purposes, or
  • Any participant who has already had a diagnostic or therapeutic procedure that has yielded tissue, blood or other bodily fluids presently in the archive but who has not yet been approached to participate is also eligible.

Part B:

  • Patients must be successfully registered to Part A of MSKCC IRB# 12-245
  • Prior written approval for patient consent obtained from the Principal/Co-Principal Investigator of MSKCC IRB # 12-245.

Part C:

  • Patient must be receiving ongoing care at MSK or a CHERPn/ Alliance/Affiliate site or have previously consulted with an MSK physician.
  • Patient must have successfully consented to Part A of this study.

Part D:

  • Patients with no personal cancer history at increased risk for cancer development due to family history, molecular cancer marker, know carrier status of a gene associated with increased cancer risk or prior/ongoing environmental exposures or lifestyle factors.

Exclusion Criteria:

All Parts:

  • Unwilling or unable to provide informed consent.

Part C:

  • All patients consenting to Part A are eligible to consent to 12-245, Part C. Most patients will be eligible to receive clinical germline testing with return of results to the patient/health care providers. However, several exclusion criteria apply and are outlined below

    1. Solid tumor patients: Secondary germline analysis using BAM files generated for MSK-IMPACT testing is not an option for patients with solid tumors and an acute or chronic hematologic neoplasm that would preclude the use of blood or saliva as a source of germline DNA. Such patient may be eligible for primary germline testing using a non-blood source of germline DNA as per standard clinical guidelines. Solid tumor patients who have had an allogenic bone marrow/stem cell transplant will only be considered eligible for germline testing under Part C if a sample adequate for germline testing had previously been collected prior to allogenic bone marrow/stem cell transplant.
    2. Hematologic cancer patients: For patients with a hematopoietic neoplasm, germline testing may be an option under Part C using nail clippings or another non-blood source of DNA as per standard clinical practice. For patients who have had an allogenic bone marrow/stem cell transplant, clinical germline testing will only be considered under Part C if a sample adequate for germline testing had previously been collected prior to Allogenic bone marrow/stem cell transplant.

Part D

  • Exclusion criteria are same as those for Part C outlined above.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Pts with solid tumors

Patients must have solid or hematologic cancer. for treatment on a . Patients must have undergone pathologic confirmation of their tumor at MSKCC and have either: 1) archival tissue available for analysis, 2) have fresh tissue collection planned as routine standard of care biopsy or part of a research biopsy under another clinical trial(or peripheral blood / bone marrow collection in the case of hematologic cancers) outside of the context of this protocol, or 3)archival tissue .available at an outside facility. For prospective genotyping tissue specimens from the primary site, a metastasis or recurrence will be used based upon the availability and quality of tissue.

Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational "next-generation" profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, & others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection & research biopsies.

Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the "ACMG list").

Part D: Germline Profiling for Individuals at Elevated Cancer Risk

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
frequency of "actionable" oncogenic mutations
大体时间:1 year

"Actionable" mutations will be defined as either 1) a mutation shown to predict for sensitivity or resistance to a drug FDA approved for use in another cancer indication or 2) a mutation which predicts for sensitivity or resistance in preclinical models to an investigational class of drugs.

1 year

次要结果测量

结果测量
措施说明
大体时间
To determine the impact of molecular profiling results performed in the CLIA-setting on the treatment of patients.
大体时间:1 year

The Bioinformatics Core will assist in interpreting data generated by next-generation sequencing techniques such as WES and WGS.

1 year
interrogate the mechanisms
大体时间:1 year

underlying response and resistance (de-novo and acquired) to targeted therapy. The research assay(s) used to accomplish this will vary based on the clinical setting and tissue available and may include Sanger, Sequenom, MiSeq, exon-capture (ie: IMPACT), whole exome, and whole genome sequencing.

1 year
To explore the genetic mechanisms of tumorigenesis
大体时间:2

in a subset of specimens with no identifiable culpritic genomic alterations on highly-multiplexed next-generation sequencing (i.e.: IMPACT testing) by using even more comprehensive investigational profiling techniques such as whole exome sequencing, whole genome sequencing or RNA sequencing

2

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:David Solit, MD、Memorial Sloan Kettering Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2013年1月1日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2027年1月1日

研究注册日期

首次提交

2013年1月21日

首先提交符合 QC 标准的

2013年1月21日

首次发布 (估计的)

2013年1月24日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅